Embecta vs ICU Medical
ICU Medical is the larger business, with $2.23bn of revenue in fiscal 2025 against $1.08bn for Embecta (2.1 times as much). Embecta grew faster (-3.8% against -6.3%). Embecta kept more of each dollar of sales as profit: a net margin of 8.8% against 0.0%.
| Latest fiscal year | EmbectaEMBC, 2025 | ICU MedicalICUI, 2025 |
|---|---|---|
| Revenue | $1.08bn | $2.23bn |
| Revenue growth | -3.8% | -6.3% |
| Net income | $95.4m | $732,000 |
| Operating margin | 22.4% | — |
| Net margin | 8.8% | 0.0% |
| Return on equity | — | 0.0% |
| Free cash flow | $182m | $91.8m |
| Cash | $226m | $308m |
| Total debt | $1.42bn | $1.29bn |
| Debt to equity | — | — |
| Dividend per share | $0.60 | — |
| Dividend yield | 7.8% | — |
| Share buybacks | — | $8.8m |
| Employees | 1,850 | 13,000 |
| Market value | $343m | $4.03bn |
| Price vs our value range | — | Above our value range |
| Moat score | 70 (Moderate) | 35 (Weak) |
| Insider trades, 12 months | 4 buys, 1 sales | 0 buys, 19 sales |